• mRNA Vaccine Targeting P1 Protein Protects Against M. pneumo

  2026-07-23

  The referenced study introduces an mRNA vaccine encoding the C-terminal region of the Mycoplasma pneumoniae P1 protein, demonstrating robust induction of antibody and T-cell responses in mice. These findings provide a promising avenue for combating rising drug-resistant M. pneumoniae infections and inform the design of targeted immunodetection assays.

• BMS 309403: Enhancing Reproducibility in FABP4 Inhibitor Ass

  2026-07-22

  This article provides evidence-based guidance for leveraging BMS 309403 (SKU B7794) in cell-based assays targeting FABP4, with a focus on reproducibility and workflow optimization. Scenario-driven Q&A blocks address selection, protocol parameters, and data interpretation for atherosclerosis and metabolic disease research. Practical recommendations are supported by quantitative data and direct links to validated resources.

• Unlocking MCL1-Driven Apoptosis: S63845 in Translational Onc

  2026-07-22

  This article explores the mechanistic and translational landscape of S63845, a potent MCL1 inhibitor, contextualizing its role in mitochondrial apoptosis and cancer research. By integrating evidence from infection biology—such as chlamydial OmpA-mediated apoptosis inhibition—and advanced cancer model workflows, it offers actionable guidance for translational researchers seeking to harness mitochondrial apoptotic pathway modulators like S63845 for therapeutic discovery.

• Gemcitabine HCl: Optimizing DNA Replication Inhibition in Pa

  2026-07-21

  Harness the full translational potential of Gemcitabine HCl by combining validated dosing regimens with advanced multianimal MRI protocols for efficient, quantitative tumor monitoring. This guide unpacks actionable workflows and troubleshooting tips for maximizing cytotoxicity assays and in vivo efficacy studies in pancreatic cancer models.

• Rotenone and the Future of Mitochondrial Dysfunction Researc

  2026-07-21

  Explore how Rotenone, a gold-standard mitochondrial Complex I inhibitor, enables translational researchers to probe mechanistic links between mitochondrial dysfunction, neurodegenerative disease, and emerging immunometabolic checkpoints. This thought-leadership article bridges rigorous mechanistic insight with actionable guidance, highlighting Rotenone’s strategic value in modeling disease-relevant pathways and integrating new findings in immunometabolic regulation.

• nor-Binaltorphimine Dihydrochloride in Opioid Receptor Resea

  2026-07-20

  nor-Binaltorphimine dihydrochloride empowers precise dissection of κ-opioid receptor signaling, enabling breakthroughs in pain modulation and neuropharmacology. This guide distills advanced protocol tips, troubleshooting strategies, and translational insights anchored in the latest mechanistic research.

• CAY10499: Enabling Precision Lipidomics in Tumor Immunometab

  2026-07-20

  Explore how CAY10499, a potent inhibitor of human hormone sensitive lipase, advances lipid metabolism assays and immunometabolic research. This article uniquely dissects protocol design and assay interpretation in the context of tumor-associated macrophage biology.

• EZ Cap EGFP mRNA 5-moUTP: Optimizing Reporter Assays & Imagi

  2026-07-19

  EZ Cap™ EGFP mRNA (5-moUTP) from APExBIO sets a new standard for reliable, high-efficiency reporter expression and in vivo imaging thanks to immune-evasive modifications and superior mRNA stability. This guide details best-practice workflows and troubleshooting strategies, leveraging recent advances in mRNA delivery nanotechnology.

• EZ Cap EGFP mRNA 5-moUTP: Optimizing Reporter Assays & Imagi

  2026-07-18

  EZ Cap™ EGFP mRNA (5-moUTP) enables highly reproducible, low-immunogenicity EGFP expression, ideal for benchmarking mRNA delivery and translation efficiency across in vitro and in vivo contexts. Its Cap 1 capping and 5-methoxyuridine modifications provide unmatched stability and immune evasion for a variety of gene expression studies.

• PD98059 (SKU A1663): Reliable MEK Inhibition for Cell Assays

  2026-07-17

  This article delivers a scenario-driven, evidence-based guide for using PD98059 (SKU A1663) in cell viability, proliferation, and cytotoxicity assays. Drawing from recent peer-reviewed findings and practical lab challenges, it outlines how PD98059 ensures reproducible MEK inhibition and robust data quality in MAPK/ERK pathway studies.

• FGFR1 as a Druggable Target in Schizophrenia: Insights from

  2026-07-17

  A comprehensive genomic and functional analysis has identified FGFR1 as a promising druggable gene for schizophrenia, leveraging Mendelian randomization, co-localization, and molecular docking techniques. This work advances the understanding of schizophrenia pathogenesis and highlights actionable targets for future therapeutic development.

• PD98059 in Precision Apoptosis and Hepatoprotection Research

  2026-07-16

  Discover how PD98059, a selective MEK inhibitor, enables advanced research in apoptosis modulation and hepatoprotection. This article uniquely examines its mechanistic role in mitochondrial apoptosis and oxidative stress, with direct protocol guidance and insights from recent in vivo studies.

• STMN2 Protein Depletion via Stress Granules in ALS Pathogene

  2026-07-16

  This study uncovers TDP-43-independent mechanisms driving STMN2 protein depletion in amyotrophic lateral sclerosis (ALS), revealing the role of translation deficits and stress granule dynamics in neuronal vulnerability. The findings highlight a compensatory RNA response and suggest new molecular targets for ALS research.

• Aurora A Regulates Trained Immunity via SAM Metabolism Contr

  2026-07-15

  Li et al. uncover a mechanistic link between Aurora kinase A (AurA) activity and the metabolic-epigenetic control of trained immunity in innate immune cells. Their work demonstrates that AurA sustains S-adenosylmethionine (SAM) levels to support histone methylation and inflammatory gene priming, providing new insight into the intersection of cancer biology and immunometabolism.

• Bifendate (DDB): Synthetic Hepatoprotection & Lipid Regulati

  2026-07-15

  Bifendate (DDB) is a synthetic hepatoprotection agent derived from Schisandrin C, offering multi-target inhibition of autophagy and regulation of lipid metabolism. It is validated for both in vitro and in vivo liver research, with specific dosing and storage guidelines. APExBIO supplies DDB under SKU BA1823, supported by mechanistic and clinical evidence.

445 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page